Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency

ConclusionsSomapacitan, compared with daily GH, did not adversely affect glucose metabolism up to 86  weeks in a large cohort of treatment-naïve or previously treated patients with AGHD.Trial registrations (date of registration): NCT02229851 (2 September 2014), NCT02382939 (3 March 2015), NCT03075644 (7 March 2017).

Source: Pituitary - February 1, 2023 Category: Endocrinology Source Type: research